PROPANC BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
PROPANC BIOPHARMA, INC. (PPCB) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $516.15 thousand for the 12-month period ending 2018-06-30, per its 10-K filed 2019-10-15.
Discontinued › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2019-10-15
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-12-31 was $165.46K.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-09-30 was $164.88K.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2018 was $516.15K, a 69.39% decline from fiscal 2017.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $1.69M, a 2.08% decline from fiscal 2016.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $1.72M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|
| 2018-06-30 | $516.15K 10-K · filed 2019-10-15 | ||
| 2017-12-31 | $165.46K 10-Q · filed 2019-05-15 | $330.34K derived: sum of 2 quarters · filed 2019-05-15 | |
| 2017-09-30 | $164.88K 10-Q · filed 2019-05-15 | ||
| 2017-06-30 | $1.69M 10-K · filed 2018-09-17 | ||
| 2016-06-30 | $1.72M 10-K · filed 2017-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |